The fight over compounded tirzepatide has mostly played out in courtrooms, regulatory announcements and FDA warning letters.
On November 4, it reached a quieter venue: the advertising industry’s own referee.
BBB National Programs’ National Advertising Division, or NAD, announced that it had recommended Good Life Meds discontinue a series of health-benefit and personalization claims for its compounded tirzepatide products, including one marketed as “Tirzepatide+.”
The challenge came from Eli Lilly, which manufactures Mounjaro and Zepbound, the FDA-approved tirzepatide medicines used for diabetes and weight management.
NAD is not a government regulator. It cannot revoke a pharmacy license, withdraw approval for a medicine or determine whether Good Life’s compounding arrangements comply with federal law.
Its role is to examine what advertising communicates to consumers and whether the advertiser has adequate evidence for those messages.
In this case, the evidence Good Life supplied concerned Lilly’s approved tirzepatide products, separate additive ingredients and research that did not adequately address the finished compounded medicine being advertised.
That distinction goes to the heart of the compounded GLP-1 business, and it is why this relatively small advertising case deserves attention.
What Good Life Meds Claimed About Compounded Tirzepatide
Good Life Meds operates an online telehealth platform connecting consumers with healthcare professionals and pharmacies. Its offerings have included compounded tirzepatide preparations marketed under the Tirzepatide+ name.
According to NAD’s November 4 announcement, Lilly challenged advertising claims suggesting that compounded tirzepatide or Tirzepatide+ supported healthy weight loss, provided natural energy boosts, improved blood sugar control and preserved lean muscle mass.
Lilly also challenged representations concerning the products’ safety, efficacy, FDA status and degree of personalization.
The distinction between a claim about an ingredient and a claim about a finished medicine became central to NAD’s analysis.
NAD determined that, when considered in the context of the advertising as a whole, the health-benefit statements communicated that Good Life’s actual compounded Tirzepatide+ product delivered the advertised benefits.
That is different from saying that tirzepatide itself has been studied in clinical trials or that an additive ingredient has been investigated separately.
NAD found that Good Life lacked an adequate basis for the challenged express health-benefit claims and recommended that they be discontinued.
It also recommended modifying advertising to avoid unsupported implied claims that the compounded product was safe and effective for those benefits or produced significant weight-loss results.
The public NAD summary does not identify the additive ingredients or their concentrations. It would therefore be inappropriate to assume what was included in the formulation based on other compounded GLP-1 products sold in the market.
The issue was not whether tirzepatide is capable of producing weight loss. Lilly’s FDA-approved medicines already have substantial clinical evidence supporting their authorized uses.
The issue was whether Good Life had enough evidence for the specific benefits its advertising attributed to Tirzepatide+.
The Evidence Good Life Offered Was About Other Products
The most instructive part of the decision is NAD’s description of the evidence Good Life submitted.
The company supplied substantial clinical literature on tirzepatide, separate research concerning the additive ingredients, a Gallup survey and retrospective cohort studies.
That is not an empty evidence file. But NAD found that the materials did not sufficiently substantiate the particular advertising claims at issue.
Much of the clinical literature concerned Lilly’s FDA-approved tirzepatide medicines. Those studies establish important information about the approved products, their tested formulations and their authorized uses.
They do not automatically establish every advertised benefit for a different finished compounded preparation.
Good Life also submitted studies of the additional ingredients. NAD found that the submitted research did not adequately connect those ingredient-level findings to Tirzepatide+ as compounded.
The Gallup survey and retrospective cohort studies presented a separate problem: according to NAD, they did not examine Tirzepatide+ itself.
Most significantly, NAD reported that the review record contained no evidence evaluating the safety of combining tirzepatide with the additives.
That absence does not prove that the finished product is harmful. It means the company had not substantiated the particular combination-related assurances communicated through the challenged advertising.
NAD also rejected reliance on FDA’s earlier shortage-related accommodation of compounding as evidence supporting the advertised benefits.
Permission to prepare a qualifying compounded medicine under specific legal conditions is not the same thing as clinical evidence establishing the safety and efficacy of that finished preparation.
The history matters here.
During periods when tirzepatide injections were in shortage, federal compounding rules provided certain pathways and enforcement flexibility for qualifying pharmacies and outsourcing facilities. Those arrangements were conditional; they never made every compounded copy or combination automatically lawful.
FDA determined that the tirzepatide injection shortage was resolved in October 2024 and reaffirmed the decision in December. Associated transition periods extended into 2025.
In February 2026, FDA announced its intention to restrict certain mass-marketed, non-approved compounded GLP-1 medicines and address misleading claims comparing them with approved products.
On March 3, FDA announced another 30 warning letters to telehealth companies whose marketing allegedly misrepresented compounded GLP-1 products or obscured who actually prepared them.
Those FDA actions were separate from the Good Life NAD proceeding. But they reflect an overlapping concern: consumers should not be led to assume that a compounded medicine has the same regulatory status and clinical substantiation as an FDA-approved product.
The broader shift is examined in our coverage of the GLP-1 telehealth enforcement era.
The weakness NAD identified was not the absence of research on tirzepatide. It was the distance between the research submitted and the claims made for Good Life’s particular compounded product.
Why the Word “Personalized” Drew a Line
The personalization finding may prove just as consequential as the health-benefit claims.
Personalization has become a prominent part of compounded GLP-1 marketing because federal compounding law recognizes circumstances in which a patient’s specific medical needs may justify a preparation different from a commercially available approved medicine.
Good Life described Tirzepatide+ using language that presented the product as individualized, tailored to patient needs and specially compounded for the person receiving it.
NAD found that the advertising conveyed a level of individual formulation that was not substantiated by the process described in the review.
A prescriber selecting among available formulations or dosage options can be making an individualized treatment decision. Adjusting that prescription over time can also reflect clinical judgment.
But those actions do not necessarily mean the medicine itself was individually created or formulated for that particular patient.
NAD accordingly recommended discontinuing the challenged descriptions of Tirzepatide+ as personalized, custom formulated or specifically compounded for each patient’s unique needs.
The distinction is uncomfortable for a telehealth market in which selecting a dose from an online treatment program can be presented as bespoke medical care.
It also requires a careful boundary.
NAD did not decide that legitimate patient-specific compounding is impossible, or that all prescribing decisions involving compounded medicines are improperly described as individualized.
Its recommendation concerned the messages conveyed by Good Life’s particular advertisements and the evidence supporting them.
Nor was this a formal FDA determination that the products failed to meet an applicable statutory condition for compounding. Advertising substantiation and compounding legality are different questions, even when their underlying facts overlap.
Choosing a dose for a patient is not automatically the same as creating a formulation specifically for that patient.
That principle is broader than one company’s product name.
Other telehealth advertisers making similar promises may need to consider whether their own product and service descriptions convey a level of customization their evidence does not substantiate.
NAD’s findings are case-specific, but the advertising question applies across an industry built partly on the promise of treatment tailored to individual needs.
What Good Life Said, and How Lilly Is Using Advertising Challenges
Good Life did not agree with every conclusion.
In its advertiser statement, the company said it disagreed with aspects of NAD’s decision but would comply with the recommendations.
During the review, Good Life had already voluntarily and permanently discontinued certain claims involving clinical results, benefits, ingredients, safety and sourcing.
NAD said those withdrawn claims would be treated, for compliance purposes, as though their discontinuation had been formally recommended.
That is not the same as NAD making an independent merits determination on every withdrawn statement.
The November 4 announcement records Good Life’s commitment to comply. It does not constitute a later audit confirming that every remaining advertising change has already been implemented.
For Lilly, the case is another part of a larger campaign addressing compounded products marketed alongside its approved tirzepatide medicines.
The company has pursued litigation against sellers of compounded tirzepatide, challenged pharmaceutical advertising and raised concerns about the quality of some compounded samples.
This is also not Lilly’s first use of NAD against compounded tirzepatide advertising.
In 2025, NAD published separate Lilly-initiated challenges involving Begin Anew MedSpa, Striker Pharmacy and Hormone Fitness. In those matters, advertisers voluntarily discontinued challenged claims, so NAD did not necessarily decide each claim on its merits.
The Good Life decision is notable because the public summary explains why the submitted evidence was insufficient for the finished product’s health-benefit claims and why the personalization language overstated what had been established.
Lilly and Novo Nordisk have also faced litigation from the compounding industry.
A federal court dismissed an antitrust case brought by Strive Specialties against the two manufacturers in August 2026, and later rejected Strive’s effort to undo the dismissal.
That separate dispute concerned pharmaceutical competition and market definition, not Good Life’s advertising evidence. We covered the distinction in our report on the Strive antitrust dismissal.
An NAD challenge can offer a different route from federal litigation. It examines specific advertising messages through an industry self-regulatory process and results in publicly stated recommendations.
NAD cannot directly impose a federal fine, but advertisers that refuse to participate or comply may be referred to government regulators, generally the Federal Trade Commission.
Good Life has said it will comply, and the public announcement does not indicate a referral arising from this decision.
What the Ruling Does Not Establish
It is worth being precise about the limits.
NAD did not find that compounded tirzepatide as a category is ineffective or necessarily unsafe.
It did not establish that Good Life’s Tirzepatide+ products were contaminated, that patients were injured or that a pharmacy dispensed the wrong substance.
It did not determine whether Good Life’s prescribing or compounding arrangements complied with federal and state pharmaceutical law.
Nor did it publish the identities and concentrations of the additives in the challenged finished products, preventing outside readers from evaluating any particular combination on the basis of the announcement alone.
The finding was narrower: Good Life had not adequately substantiated the challenged messages its advertising conveyed about the finished Tirzepatide+ preparation.
That distinction matters for patients as much as it does for advertisers.
Compounded medicines can serve legitimate medical needs under appropriate legal conditions. But they are not FDA-approved products, and the agency does not conduct the same premarket assessment of their safety, effectiveness and quality that it performs for approved medicines.
Patients may seek compounded GLP-1 treatments because they face coverage limitations, high costs or particular medical needs. Those motivations can be real even when advertising for a specific compounded product is inadequately supported.
The central consumer question is therefore not simply whether a product contains a familiar active ingredient.
It is what evidence supports the actual medicine being prescribed and the specific claims made about it.
Studies of Mounjaro or Zepbound can help establish the clinical properties of approved tirzepatide medicines. They do not automatically demonstrate that a separately prepared, additive-containing product will deliver every benefit an advertiser promises.
For a market that has frequently sold the idea of a lower-cost alternative to branded treatment, the distinction is significant.
Lilly brought an advertising challenge. NAD examined the evidence behind Good Life’s promises. And the clearest finding was that the evidence supplied did not adequately describe the finished product being sold.
The molecule may be familiar. The finished medicine still needs evidence for the claims made about it.
Sources
Primary decision summary: BBB National Programs — National Advertising Division Recommends Good Life Discontinue Health Benefit and Personalization Claims for Compounded Tirzepatide+ Products. November 4, 2026.
Original distributed announcement: BBB National Programs via GlobeNewswire — Good Life Meds NAD Decision Summary. November 4, 2026.
FDA enforcement announcement: FDA — FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. March 3, 2026.
FDA compounding policy: FDA — Policies for Compounders as National GLP-1 Supply Stabilizes. Includes the December 2024 tirzepatide shortage decision and associated enforcement policies.
FDA advertising guidance: FDA — What Telehealth Companies Should Know When Promoting Compounded Drugs.
Earlier related NAD proceedings: BBB National Programs — Begin Anew MedSpa Compounded Tirzepatide Claims. June 3, 2025.
Compounding litigation context: Reuters — Lilly and Novo Defeat Antitrust Lawsuit Over GLP-1 Drug Market. August 6, 2026.
Additional reporting: BioSpace — FDA Sends 30 Warning Letters to Continue Clampdown on Compounded GLP-1s. March 4, 2026.
